Draft:SK Biopharmaceuticals
Submission declined on 4 June 2025 by Sophisticatedevening (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 10 March 2025 by Theroadislong (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. Declined by Theroadislong 7 months ago. | |
| Submission declined on 6 March 2025 by SK2242 (talk). Procedural decline. This draft was resubmitted with zero improvement to address the issues raised by the previous reviewer. Declined by SK2242 7 months ago. | |
| Submission declined on 5 March 2025 by Cyberdog958 (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. Declined by Cyberdog958 7 months ago. | |
 | This article may incorporate text from a large language model. (March 2025) |
SK Biopharmaceuticals
[edit]| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2011 |
| Headquarters | Bundang, Seongnam, South Korea |
| Parent | SK Group |
| Website | www |
SK Biopharmaceuticals Co., Ltd. is a South Korean biopharmaceutical company specializing in the research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology. It operates as a subsidiary of the SK Group and is headquartered in Bundang, Seongnam, Gyeonggi Province, South Korea.
History
[edit]SK Biopharmaceuticals originated as a division of SK Chemicals in 1993 and became an independent company in 2011. The company focuses on CNS therapeutics and gained industry recognition after developing cenobamate (XCOPRI®), an anti-epileptic drug that received approval from the U.S. Food and Drug Administration (FDA) in November 2019.[1]
In July 2020, SK Biopharmaceuticals was listed on the Korea Exchange (KRX).[2]
Research and Development
[edit]SK Biopharmaceuticals engages in research and development across multiple therapeutic areas.
CNS Therapeutics
[edit]Cenobamate (XCOPRI®/ONTOZRY®): Approved for treating partial-onset seizures in adults. By March 2024, over 100,000 patients worldwide had been treated with cenobamate.[3]
Solriamfetol (SUNOSI®): A treatment for excessive daytime sleepiness in patients with narcolepsy and obstructive sleep apnea. Developed by SK Biopharmaceuticals and later out-licensed.[4]
Oncology and Radiopharmaceuticals
[edit]Radiopharmaceutical Therapy (RPT): The company has secured supply agreements for Actinium-225 (Ac-225) with TerraPower and PanTera for use in radiopharmaceutical cancer treatments.[5] Targeted Protein Degradation (TPD): Developing oncology treatments through SK Life Science Labs, its U.S. subsidiary.[6]
Recent Developments
[edit]In April 2024, the FDA approved new administration methods for XCOPRI®, allowing tablets to be crushed and taken orally or via a nasogastric tube for patients with partial-onset seizures.[7]
References
[edit]- ^ "FDA approves new treatment for adults with partial-onset seizures". U.S. Food and Drug Administration. November 21, 2019. Retrieved March 7, 2025.
- ^ "SK Biopharmaceuticals makes successful market debut on Korea Exchange". The Korea Times. July 2, 2020. Retrieved March 7, 2025.
- ^ "Angelini Pharma and SK Biopharmaceuticals announce treatment of over 100,000 patients globally with cenobamate". PharmaTimes. March 11, 2024. Retrieved March 7, 2025.
- ^ "SK Life Science: A History of Discovery". SK Life Science. Retrieved March 7, 2025.
- ^ "SK Biopharmaceuticals secures Actinium-225 for next-gen radiopharmaceuticals". Business Korea. August 28, 2023. Retrieved March 7, 2025.
- ^ "SK Life Science Labs: About Us". SK Life Science Labs. Retrieved March 7, 2025.
- ^ "FDA approves alternate administration for SK Biopharmaceuticals' XCOPRI". PR Newswire. April 2024. Retrieved March 7, 2025.
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.